Oscient Pharmaceuticals plans exchange offer for 3.5% convertibles

By Angela McDaniels

Tacoma, Wash., Sept. 10 - Oscient Pharmaceuticals Corp. plans to hold an exchange offer under which it will issue up to $67.71 million of new 12.5% convertible senior notes due April 15, 2011 and shares of common stock for its $225.7 million of outstanding 3.5% convertible senior notes due Jan. 15, 2011.

Under the offer, holders who exchange will receive $300 principal amount of the new 12.5% convertibles and Oscient shares having a value equal to $200 for each $1,000 principal amount of 3.5% convertibles, according to a company news release. The company will also pay accrued interest.

The 12.5% convertibles will have a conversion price equal to 110% of the average of the stock's daily volume-weighted average price for the five trading days prior to the second business day before the exchange offer's expiration date, provided that the conversion price be at least $1.10 per share.

The conversion price of the 3.5% convertibles is $13.50 per share. Oscient stock closed at $1.17 (Nasdaq: OSCI) on Tuesday.

Interest on the 12.5% convertibles will be payable in cash or in kind. Interest on the 3.5% convertibles is payable only in cash.

The 12.5% convertibles will become callable at par on Oct. 15, 2010. The 3.5% convertibles become callable at par on May 10, 2010.

Like the 3.5% convertibles, the 12.5% convertibles can be automatically converted by the company if the share price exceeds 130% of the conversion price for 20 or more trading days during any 30-trading-day period.

The company said it believes the exchange offer is an important component of its plan to reduce its overall debt level and re-calibrate its capital structure to better execute its business strategy.

An S-4 registration statement for the new convertibles was filed with the Securities and Exchange Commission on Wednesday, and the offer may not begin until the registration has been declared effective.

Lazard Capital Markets LLC and MTS Securities, LLC will be the dealer managers for the exchange offer, and Altman Group, Inc. (866 751-6316) will be the information agent.

Oscient is a Waltham, Mass.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.